A Prospective, Multicenter, Randomised, Double-blinded, Placebo-controlled, Two-parallel Groups, Phase III Study to Compare the Efficacy and Safety of Masitinib to Placebo in Patients With Localized, Primary Gastrointestinal Stromal Tumor (GIST) After Complete Surgery and With High Risk of Recurrence
Latest Information Update: 05 Oct 2021
At a glance
- Drugs Masitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Sponsors AB Science
- 03 Dec 2018 Status changed from recruiting to discontinue as per sponsor decision based on portfolio prioritization
- 18 Dec 2013 New trial record